Peter W. Radke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter W. Radke has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Heribert Schunkert
Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany
3 shared publications - Christof Burgdorf
Department of Cardiology, Heart and Vascular Center Bad Bevensen, Bad Bevensen, Germany
2 shared publications Volkhard Kurowski
Department of Internal Medicine II, University Hospital Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
2 shared publications- Adnan Kastrati
Deutsches Herzzentrum München
1 shared publication - Alexander Joost
DZHK Partner Site Hamburg-Kiel-Lübeck, Hamburg, Germany
1 shared publication Alexander Meyer
Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin , Berlin, Germany
1 shared publication
Latest Publications
- 16 June 2023
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 165 (12) , 35-37
Prophylaxe venöser Thrombembolien im ambulanten Bereich
- 16 June 2023
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 165 (12) , 35-37
Prophylaxe venöser Thrombembolien im ambulanten Bereich
- 9 February 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (3)
Prognostic impact of secondary prevention after coronary artery bypass grafting—insights from the TiCAB trial
There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year outcome after CABG. Data were taken from the randomized ‘Ticagrelor in CABG’ trial. From April 2013 until April 2017, patients who underwent CABG were included. For the present analysis, we compared patients who were treated with optimal medical secondary prevention with those where 1 or more of the recommended medications were missing. Follow-up data at 12 months were available in 1807 patients. About half (54%) of them were treated with optimal secondary prevention. All-cause mortality [0.5% vs 3.5%, hazard ratio (HR) 0.14 (0.05–0.37), P < 0.01], cardiovascular mortality [0.1% vs 1.7%, HR 0.06 (0.01–0.46), P = 0.007] and major adverse events [6.5% vs 11.5%, HR 0.54 (0.39–0.74), P < 0.01] were significantly lower in the group with optimal secondary prevention. The multivariable model for the primary end point based on binary concordance to guideline recommended therapy identified 3 independent factors: adherence to guideline recommended therapy [HR 0.55 (0.39–0.78), P < 0.001]; normal renal function [HR 0.99 (0.98–0.99), P = 0.040]; and off-pump surgery [HR 2.06 (1.02–4.18), P = 0.045]. Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.
- 9 February 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (3)
Prognostic impact of secondary prevention after coronary artery bypass grafting—insights from the TiCAB trial
There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year outcome after CABG. Data were taken from the randomized ‘Ticagrelor in CABG’ trial. From April 2013 until April 2017, patients who underwent CABG were included. For the present analysis, we compared patients who were treated with optimal medical secondary prevention with those where 1 or more of the recommended medications were missing. Follow-up data at 12 months were available in 1807 patients. About half (54%) of them were treated with optimal secondary prevention. All-cause mortality [0.5% vs 3.5%, hazard ratio (HR) 0.14 (0.05–0.37), P < 0.01], cardiovascular mortality [0.1% vs 1.7%, HR 0.06 (0.01–0.46), P = 0.007] and major adverse events [6.5% vs 11.5%, HR 0.54 (0.39–0.74), P < 0.01] were significantly lower in the group with optimal secondary prevention. The multivariable model for the primary end point based on binary concordance to guideline recommended therapy identified 3 independent factors: adherence to guideline recommended therapy [HR 0.55 (0.39–0.78), P < 0.001]; normal renal function [HR 0.99 (0.98–0.99), P = 0.040]; and off-pump surgery [HR 2.06 (1.02–4.18), P = 0.045]. Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.
- 16 December 2020
- Vol. 20 (6) , 51-57
Literatur kompakt
- 10 June 2020
- Published by Springer Nature in CardioVasc
- Vol. 20 (3) , 43
Deutlich weniger akute STEMI-Interventionen während der COVID-19-Pandemie
- 10 June 2020
- Published by Springer Nature in CardioVasc
- Vol. 20 (3) , 43
Deutlich weniger akute STEMI-Interventionen während der COVID-19-Pandemie
- 15 December 2017
- Published by Springer Nature in Herz
- Vol. 43 (1) , 34-42
Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie
Aufgrund ihrer verwandten Pathophysiologie werden die tiefe Beinvenenthrombose sowie die Lungenarterienembolie unter dem Begriff „venöse Thrombembolien“ (VTE) zusammengefasst. Während die Inzidenz dieser Erkrankungen durch den demographischen Wandel sowie die verbesserte Diagnostik seit Jahren zunimmt, sinken Morbidität und Mortalität. Dies ist v. a. Folge sensitiverer Diagnostik, verbesserter Risikostratifizierung sowie effektiverer Strategien zur Antikoagulation, deren Ziel die Verhinderung früher Ereignisse bis hin zum Tod sowie die Prävention von Rezidiven darstellt. Die Antikoagulationstherapie sollte entweder zunächst mit Heparinen (unfraktioniert oder niedermolekular), Fondaparinux oder auch direkten oralen Antikoagulanzien begonnen werden. Patienten mit einem Rezidivereignis qualifizieren sich für eine dauerhafte Antikoagulation. Bei einem Erstereignis sollte die Antikoagulationstherapie für mindestens 3 Monate erfolgen (Erhaltungstherapie). Nachfolgend kann in Abhängigkeit vom individuellen Risiko (Rezidiv, Blutung) eine verlängerte Erhaltungstherapie im Sinne der Sekundärprävention sinnvoll sein. Hierzu sind mittlerweile auch Nicht-Vitamin-K-abhängige Antikoagulanzien (NOAK) zugelassen. Aufgrund des wahrscheinlich dauerhaft hohen Rezidivrisikos von bis zu 10 % pro Jahr nach Absetzen der Antikoagulation, unzureichender Scores zur Abschätzung des Blutungsrisikos sowie vielversprechender Sicherheitsprofile von NOAK in der Sekundärprävention ist zukünftig von einer Zunahme länger (>3–6 Monate) bis dauerhaft (>1 Jahr) antikoagulierter Patienten nach thromboembolischen Erkrankungen auszugehen. Deep vein thrombosis and pulmonary artery embolisms share pathophysiological features and are therefore collectively referred to as venous thromboembolisms (VTE). While the incidence of VTE has been increasing for years as a result of demographic changes and improved diagnostics, the morbidity and mortality are decreasing. This is particularly due to more sensitive diagnostics, improvements in risk stratification and more effective anticoagulation strategies. The aim of effective anticoagulation therapy is the avoidance of early events up to death and prevention of recurrent events. Anticoagulation treatment should be started with either heparins (unfractionated or low molecular weight), the pentasaccharide fondaparinux or direct oral anticoagulants. Patients with recurrent events qualify for indefinite anticoagulation treatment. For a first episode of VTE anticoagulation treatment for at least 3 months is recommended (maintenance therapy). Subsequently, prolonged maintenance therapy for secondary prevention can be meaningful, depending on the individual patient risk (provoked event, risk for recurrence or bleeding). The non-vitamin K antagonist oral anticoagulants (NOACs) have now also been approved for this indication. As a result of a probably permanently high risk for recurrent events of up to 10% per year after cessation of anticoagulation, insufficient scores for estimation of the risk of bleeding and recent data documenting the safety and efficacy of NOACs for secondary prevention, a shift towards prolonged anticoagulation of 3–6 months or even indefinite (>1 year) treatment can be anticipated for patients after thromboembolic diseases.
- 15 December 2017
- Published by Springer Nature in Herz
- Vol. 43 (1) , 34-42
Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie
Aufgrund ihrer verwandten Pathophysiologie werden die tiefe Beinvenenthrombose sowie die Lungenarterienembolie unter dem Begriff „venöse Thrombembolien“ (VTE) zusammengefasst. Während die Inzidenz dieser Erkrankungen durch den demographischen Wandel sowie die verbesserte Diagnostik seit Jahren zunimmt, sinken Morbidität und Mortalität. Dies ist v. a. Folge sensitiverer Diagnostik, verbesserter Risikostratifizierung sowie effektiverer Strategien zur Antikoagulation, deren Ziel die Verhinderung früher Ereignisse bis hin zum Tod sowie die Prävention von Rezidiven darstellt. Die Antikoagulationstherapie sollte entweder zunächst mit Heparinen (unfraktioniert oder niedermolekular), Fondaparinux oder auch direkten oralen Antikoagulanzien begonnen werden. Patienten mit einem Rezidivereignis qualifizieren sich für eine dauerhafte Antikoagulation. Bei einem Erstereignis sollte die Antikoagulationstherapie für mindestens 3 Monate erfolgen (Erhaltungstherapie). Nachfolgend kann in Abhängigkeit vom individuellen Risiko (Rezidiv, Blutung) eine verlängerte Erhaltungstherapie im Sinne der Sekundärprävention sinnvoll sein. Hierzu sind mittlerweile auch Nicht-Vitamin-K-abhängige Antikoagulanzien (NOAK) zugelassen. Aufgrund des wahrscheinlich dauerhaft hohen Rezidivrisikos von bis zu 10 % pro Jahr nach Absetzen der Antikoagulation, unzureichender Scores zur Abschätzung des Blutungsrisikos sowie vielversprechender Sicherheitsprofile von NOAK in der Sekundärprävention ist zukünftig von einer Zunahme länger (>3–6 Monate) bis dauerhaft (>1 Jahr) antikoagulierter Patienten nach thromboembolischen Erkrankungen auszugehen. Deep vein thrombosis and pulmonary artery embolisms share pathophysiological features and are therefore collectively referred to as venous thromboembolisms (VTE). While the incidence of VTE has been increasing for years as a result of demographic changes and improved diagnostics, the morbidity and mortality are decreasing. This is particularly due to more sensitive diagnostics, improvements in risk stratification and more effective anticoagulation strategies. The aim of effective anticoagulation therapy is the avoidance of early events up to death and prevention of recurrent events. Anticoagulation treatment should be started with either heparins (unfractionated or low molecular weight), the pentasaccharide fondaparinux or direct oral anticoagulants. Patients with recurrent events qualify for indefinite anticoagulation treatment. For a first episode of VTE anticoagulation treatment for at least 3 months is recommended (maintenance therapy). Subsequently, prolonged maintenance therapy for secondary prevention can be meaningful, depending on the individual patient risk (provoked event, risk for recurrence or bleeding). The non-vitamin K antagonist oral anticoagulants (NOACs) have now also been approved for this indication. As a result of a probably permanently high risk for recurrent events of up to 10% per year after cessation of anticoagulation, insufficient scores for estimation of the risk of bleeding and recent data documenting the safety and efficacy of NOACs for secondary prevention, a shift towards prolonged anticoagulation of 3–6 months or even indefinite (>1 year) treatment can be anticipated for patients after thromboembolic diseases.
- 25 June 2016
- Published by Springer Nature
- p. 1-7
Herzkatheter
- 1 June 2016
- Published by Springer Nature
- p. 1-12
EKG, Belastungs-EKG
- 1 January 2016
- Published by Springer Nature
- p. 1-5
Echokardiographie
- 21 March 2014
- Published by Taylor & Francis in Acute Cardiac Care
- Vol. 16 (2) , 41-48
Networks for improving care in patients with acute coronary syndrome: A framework
In recent years, it has become evident that the level of guideline adherence in patients presenting with acute coronary syndrome (ACS) is highly correlated with patient outcomes. Unfortunately, guideline adherence is low in some geographic areas and especially in those patients at high-risk. Regional networks including ambulance systems and hospitals with catheterization laboratories are able to increase guideline adherence and patient outcomes by streamlining the critical pre- and intra-hospital processes as well as improving timely access to invasive procedures and recommended medication. Successful organization of an ACS network requires engagement of multiple stakeholders to create effective solutions for the specific local setting. There is no ‘one-size-fits all’ strategy to set-up and successfully run an ACS network. We present a framework for how to set up and organize an effective ACS network, delivering guideline-based care to improve patient outcomes.
- 21 March 2014
- Published by Taylor & Francis in Acute Cardiac Care
- Vol. 16 (2) , 41-48
Networks for improving care in patients with acute coronary syndrome: A framework
In recent years, it has become evident that the level of guideline adherence in patients presenting with acute coronary syndrome (ACS) is highly correlated with patient outcomes. Unfortunately, guideline adherence is low in some geographic areas and especially in those patients at high-risk. Regional networks including ambulance systems and hospitals with catheterization laboratories are able to increase guideline adherence and patient outcomes by streamlining the critical pre- and intra-hospital processes as well as improving timely access to invasive procedures and recommended medication. Successful organization of an ACS network requires engagement of multiple stakeholders to create effective solutions for the specific local setting. There is no ‘one-size-fits all’ strategy to set-up and successfully run an ACS network. We present a framework for how to set up and organize an effective ACS network, delivering guideline-based care to improve patient outcomes.
- 1 January 2014
- Published by Springer Nature
- p. 1-11
EKG, Belastungs-EKG